Business
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
First in class drug illustrates early signal of transport of key amyloid marker from brain TSX Ex...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nFirst in class drug illustrates early signal of transport of key amyloid\nmarker from brain\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Nov. 10 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX)\nannounced today that treatment with its lead drug RVX-208, a first in class\nApoA-I/Prebeta-HDL elevating drug, in a post-hoc analysis from the Phase 1a\nclinical trial found that treatment with RVX-208 resulted in a positive trend\non an important marker of cognitive function and Alzheimer's disease,\nAmyloid-beta40 is an important constituent of amyloid plaques in the brains of\nAlzheimer's patients. The analysis of the plasma markers for Alzheimer's\ndisease was performed by Dr. D. Larry Sparks, Senior Scientist and Head of the\nRoberts Laboratory for Neurodegenerative Disease Research at Sun Health\nResearch Institute in Sun City, Arizona.\n\n\nThe Phase 1a trial, a double-blind, dose-escalation, placebo-controlled\ntrial enrolled 24 subjects in three separate dosing cohorts for a period of\none week: 6 received placebo, and 6 received 2mg/kg per day, 6 received 3mg/kg\nper day and 6 received 8 mg/kg per day of RVX-208. Plasma levels of A-beta\n(A-beta40) were measured on day 1 and 7. A 12-14 percent increase in plasma\nA-beta40 levels was observed at the highest dose of RVX-208 after 7 days of\ndosing. Based on the study hypothesis these results trended towards\nsignificance versus placebo, even with the minimal number of study subjects.\n\n\nEmerging evidence from large epidemiology studies such as the Harvard\nWomen's Study, the Honolulu-Asia Aging Study and the Whitehall II study\ncontinue to build support for the relationship between poor HDL and ApoA-I\nlevels and decreased cognitive function and Alzheimer's disease. Dr. Sparks's\ninvestigation of elective statin use and fractionated cholesterol levels in\nthe ADAPT cohort has identified a significant relationship between elevated\nHDL levels and better performance on the Mini Mental State Examination (MMSE),\nand a significant inverse relationship between increased total and LDL\ncholesterol and learning and memory. Elevated cholesterol levels are thought\nto increase the production and accumulation of the putative AD neurotoxin,\namyloid-beta (A-beta). The A-beta peptide is produced by aberrant cleavage of\na larger precursor protein resulting in two lengths...